The Salt Study for Heart Failure

This study, called "The Salt Study for Heart Failure," is looking into whether a low-sodium (salt) diet is truly necessary for people who have experienced heart failure. Researchers want to see if different salt intakes affect how often patients need to be readmitted to the hospital within 30 days of discharge. You might be able to join if you are over 18 and have been hospitalized for heart failure within the last 24 hours. However, you cannot participate if you have very high blood pressure, end-stage kidney disease (on dialysis), or cardiogenic shock (a severe type of heart failure). The study is comparing a "Normal Salt Diet" (3-4 grams of salt per day) with a "Cardiac Diet" (2 grams of salt per day), which is the standard recommendation. The study aims to understand if a normal salt diet is safe and effective for patients with acute heart failure. The current status of the study is unclear, and it plans to enroll 500 participants.

Study design
This interventional study plans to enroll 500 participants. It compares two different diets: a Normal Salt Diet and a Cardiac Diet.
What's involved
You would follow either a Normal Salt Diet or a Cardiac Diet while in the hospital. After discharge, you would follow routine clinical care recommendations.
Compensation
Not stated in the trial record.
Follow-up
Researchers will track your length of hospital stay, 30-day readmission after discharge, and NT-proBNP levels (a marker for heart failure) from admission up to 30 days after discharge.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07560592

The Salt Study for Heart Failure

Recruiting
NAAges 18+Interventional
Maya Guglin, MD
~500 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Normal Salt DietCardiac Diet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Length of hospital stay
Measured over Hospital admission to time of discharge assessed up to 1 year
+3 more outcomes measured
Heart Failure

NCT07560592

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Robert Wood Johnson Barnabas Hospital - New Brunswick

    New Brunswick, New Jerseystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Maya Guglin, MD · PRINCIPAL_INVESTIGATOR · Rutgers University

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Above 18 years of age
Hospitalization due to Heart Failure admitted within 24 hours

Exclusion

Concomitant hypertension (blood pressure \>150/90 mmHg on admission)
End stage renal disease (on hemodialysis or peritoneal dialysis
Cardiogenic shock
  • Length of hospital stayHospital admission to time of discharge assessed up to 1 year

    number of days the patient remains hospitalized

  • 30-day readmission30 days after discharge from hospital after index event

    readmission to hospital within 30 days of discharge from the index event

  • NT-proBNP on dischargetime of hospital admission to 30 days after discharge

    Measurement of blood levels of NT-ProBNP a biomarker for diagnosing and assessing the severity of heart failure.

  • Loop diuretic requirement during index admissiontime of hospital admission to 30 days after discharge

    Furosemide, torsemide, and bumetanide are specific loop diuretics used in the treatment of fluid overload / retention conditions like congestive heart failure.